Biocon

    BIOCON
    Pharma
    ₹390.65
    price as of 11/9/2026, 5:27:57 pm

    Market cap ₹63,609 Cr

    P/E
    113.23
    Day range
    ₹384.65 – ₹396.85
    52-week range
    ₹337.05 – ₹447.15
    Volume
    36.65 L
    Open
    ₹391.55
    Prev close
    ₹391.65
    Promoters pledged 4.0% of their shares
    52-week range, adjusted for splits and bonuses
    ₹337.05₹447.15
    30 Sept 202516 Jul 2026
    Index membership & F&O
    NIFTY 200NIFTY 500NIFTY MIDCAP 150NIFTY HEALTHCARENIFTY PHARMAF&O lot 2,500

    Price history

    6M change -1.19%RSI (14) 31.8 NeutralSMA 20 · 50 overlaid

    Price & delivery on the exchange

    NSE bhavcopy to 11 Sept 2026 · delivery 44.1% today vs 49.4% average · BSE close ₹390.95

    1 Apr23 Apr15 May5 Jun24 Jun15 Jul3 Aug21 Aug11 Sept₹330₹360₹390₹420₹4500%25%50%75%100%
    • Delivery
    • NSE close
    • BSE close

    High delivery with a rising price suggests buyers holding rather than trading the move.

    Futures & options

    NSE F&O close, 11 Sept 2026 · options expiring 29 Sept 2026

    Short build-up
    Near-month future
    ₹391.9
    Change
    -0.15%
    Basis over spot
    +₹1.24
    Futures OI (shares)
    5.62 Cr
    OI change
    +2.73%
    Put-call ratio
    0.46
    Max pain
    ₹400
    Resistance (call OI)
    ₹420
    Support (put OI)
    ₹380
    Lot size
    2,500

    Open interest by strike

    Calls open above (resistance) and puts below (support), in shares

    340355365375385395405415425435445455465480500020.0 L40.0 L60.0 L80.0 Lspot
    • Call OI
    • Put OI

    Futures open interest and price

    Near-month future, day by day since collection began

    The daily history builds from each close.

    Key metrics

    P/E (TTM)
    122.9
    EPS (TTM)
    ₹3.38
    Price / Book
    1.88
    ROE (FY26)
    1.3%
    ROCE (latest year)
    4%
    Dividend yield
    0.13%
    Net margin (TTM)
    2.4%
    Current ratio
    1.22
    Debt / Equity
    0.33
    Revenue growth (5y)
    18.8%
    EPS growth (5y)
    -14.6%

    Moving averages (NSE)

    Simple moving averages of the NSE price, and where the last price sits against each
    5-day10-day20-day50-day100-day300-day
    ₹398.75Price below₹407Price below₹412Price below₹420.61Price below₹411.08Price below₹396.28Price below

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +14.8%
    Profit 3Y CAGR
    -16.9%
    Revenue YoY (Jun 2026)
    +10.0%
    Profit YoY (Jun 2026)
    +53.9%
    Operating margin
    20.0%
    Net margin
    3.2%

    Revenue, profit & margin - quarterly

    Bars in ₹ crore (a loss shows red); line is operating margin

    Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Jun 2026-2.0K Cr0 Cr2.0K Cr4.0K Cr6.0K Cr0%6%12%18%24%
    • Revenue
    • Net profit
    • Operating margin

    Who owns the company

    Shareholding as of Jun 2026

    • Promoter
    • Public
    • DII
    • FII
    • Government
    • Others

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-15.0KCr-7.5K Cr0 Cr7.5K Cr15.0K Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY17FY18FY19FY20FY21FY22FY23FY24FY25FY260%5%10%15%20%15%

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); line is debt-to-equity

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 20260 Cr9.0K Cr18.0K Cr27.0K Cr36.0K Cr0.0x0.3x0.6x0.9x1.2x
    • Equity
    • Debt
    • Debt / equity

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
    Sales3,4623,9543,9173,4333,5903,8214,4173,9424,2964,1734,5174,336
    Expenses2,7453,0513,0042,8122,9053,0703,3393,1763,4603,3403,4963,489
    Operating Profit7179039136206857521,0787668358341,020847
    OPM %21%23%23%18%19%20%24%19%19%20%23%20%
    Other Income134587401,1665853576281-176-2841
    Interest248267227236226223212277272210232213
    Depreciation389414407405420425436455473515513547
    Profit before tax2148083191,1469815648797171-68248128
    Tax %19%7%30%25%72%48%6%8%22%-24%20%-7%
    Net Profit173753223862278145989133-52199137
    EPS in Rs₹1.05₹5.50₹1.13₹5.49₹-0.13₹0.21₹2.87₹0.23₹0.63₹1.08₹0.78₹0.87

    From company filings, updated 11 Sept 2026. Consolidated figures where the company reports them.Information only, not investment advice.

    Strengths, risks & growth

    Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

    Strengths

    None flagged by the checklist.

    Risks

    • Company has low interest coverage ratio.
    • Company has a low return on equity of 3.49% over last 3 years.
    • Company might be capitalizing the interest cost
    • Dividend payout has been low at 10.9% of profits over last 3 years
    • Promoter holding has decreased over last 3 years: -16.0%

    Compounded Sales Growth

    10 Years
    +18%
    5 Years
    +19%
    3 Years
    +15%
    TTM
    +10%

    Compounded Profit Growth

    10 Years
    +1%
    5 Years
    -12%
    3 Years
    -15%
    TTM
    +100%

    Stock Price CAGR

    10 Years
    +10%
    5 Years
    +2%
    3 Years
    +13%
    1 Year
    +7%

    Return on Equity

    10 Years
    +6%
    5 Years
    +4%
    3 Years
    +3%
    Last Year
    +1%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderSept 2025Dec 2025Mar 2026Jun 2026Change
    Promoter54.45%54.45%44.91%44.68%-0.23 pp
    FII6.61%7.39%7.52%8.14%+0.62 pp
    DII22.06%21.67%24.01%23.33%-0.68 pp
    Government0.03%0.03%0.05%0.05%0.00 pp
    Public16.70%16.34%23.40%23.75%+0.35 pp
    Others0.14%0.12%0.09%0.05%-0.04 pp

    Filed with NSE for Jun 2026: promoters 44.68%, public 55.27% · XBRL filing

    Analysts & fund holdings

    64%
    64% recommend buy
    14 analysts cover the stock
    Valuation vs Biotechnology
    P/E113.2 vs 46.4
    Sector P/B5.84
    Beta0.89

    Who holds the shares, quarter by quarter

    Mutual funds 15.47% (-1.06 pp)
    Jun 25
    Sept 25
    Dec 25
    Jan 26
    Mar 26
    Jun 26
    • Promoters44.7%
    • Foreign institutions8.1%
    • Mutual funds15.5%
    • Insurance6.4%
    • Other domestic institutions1.6%
    • Retail5.8%
    • Others18.0%
    Mutual funds holding the most
    Fund% of company% of fund3-month change
    SBI Contra Fund2.44%3.47%-0.07 pp
    SBI Large & Midcap Fund1.43%2.29%+0.24 pp
    Kotak Mid Cap Fund0.99%0.97%+0.97 pp
    SBI Midcap Fund0.95%2.62%-0.08 pp
    Kotak Large & Mid Cap Fund0.82%1.73%+0.18 pp

    Scorecard

    Performance
    Low
    Valuation
    High
    Growth
    Low
    Profitability
    High
    Entry point
    Good
    Red flags
    Low

    Analyst coverage, holdings and scorecard from market data; not a recommendation by Parasram India.

    Corporate actions

    • dividend
      Not available — not reported in this filing

      Dividend - Re 0.50 Per Share

      3 Jul 2026
      ex-date
    • dividend
      ₹0.50

      Dividend - Rs 0.50 Per Share

      4 Jul 2025
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend - Re 0.50 Per Share

      5 Jul 2024
      ex-date
    • dividend
      ₹1.50

      Dividend - Rs 1.50 Per Share

      7 Jul 2023
      ex-date
    • dividend
      ₹0.50

      Dividend - Rs 0.50 Per Share

      30 Jun 2022
      ex-date
    • dividend
      ₹0.50

      Dividend - Rs 0.50 Per Share

      18 Jul 2019
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 1:1

      12 Jun 2019
      ex-date
    • dividend
      Not available — not reported in this filing

      Dividend- Re 1 Per Share

      19 Jul 2018
      ex-date
    • dividend
      Not available — not reported in this filing

      Annual General Meeting/Dividend - Re 1/- Per Share

      20 Jul 2017
      ex-date
    • bonus
      Not available — not reported in this filing

      Bonus 2:1

      15 Jun 2017
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      22 Jun 2016
      ex-date
    • dividend
      ₹5.00

      Interim Dividend - Rs 5/- Per Share (Purpose Revised)

      17 Mar 2016
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      16 Jul 2015
      ex-date
    • dividend
      ₹5.00

      Interim Dividend Rs 5/- Per Share

      9 Apr 2015
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting / Final Dividend - Rs 5/- Per Share

      10 Jul 2014
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting/Final Dividend Rs 5/- Per Share + Special Dividend Rs 2.5/- Per Share

      11 Jul 2013
      ex-date
    • dividend
      ₹5.00

      Annual General Meeting / Dividend Rs 5 Per Share

      5 Jul 2012
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend Rs 3 Per Share

      7 Jul 2011
      ex-date
    • dividend
      ₹1.50

      Interim Dividend-Rs.1.50 Per Share (Purpose Revised)

      5 May 2011
      ex-date
    • dividend
      ₹3.50

      Annual General Meeting And Dividend Rs.3.50 Per Share

      8 Jul 2010
      ex-date

    Company announcements

    Company Update
    Communication Regarding Remittance Of Final Dividend For The FY 2025-26

    Communication regarding remittance of final dividend for the FY 2025-26

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)

    Company Update
    Announcement under Regulation 30 (LODR)-Press Release / Media Release

    Press Release

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Meetings with Analyst(s)/Institutional Investor(s)

    Company Update
    Communication Regarding Remittance Of Final Dividend For The FY 2025-26

    Communication regarding remittance of final dividend for the FY 2025-26

    Insider Trading / SAST
    Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

    The Exchange has received the revised disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mylan Inc.

    Company Update
    Company Statement
    Company Update
    Company Statement
    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Investor Meet

    Company Update
    Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    Earning call Transcript for Q1 FY27

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting Results and Scrutinizer's report

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Investor Meet

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper Advertisement

    Company Update
    Announcement under Regulation 30 (LODR)-Resignation of Statutory Auditors

    Resignation of Statutory auditors of material subsidiaries of the Company.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Directorate

    Change in Directorate

    Filed with BSE (scrip 532523); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Regulatory orders

    • Order

      Order in respect of Mr. Kunal Kashyap and Allegro Capital Pvt. Ltd. in the matter of Biocon Ltd.

      8 Jul 2021
      Read on SEBI
    • Order

      Order in respect of Mr. Shreehas P Tambe in the matter of Biocon Ltd. [SAT Appeal No.: 491/2021]

      30 Jun 2021
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Narendra Chirmule and Biocon Ltd., in the matter of Biocon Ltd.,

      19 May 2021
      Read on SEBI
    • Final order

      Final Order in the matter of Biocon Limited

      5 May 2021
      Read on SEBI
    • Adjudication order

      Adjudication Order in respect of Mr. P. Ravishankar in the matter of Biocon Limited

      28 Oct 2020
      Read on SEBI

    Documents

    Annual reports

    Earnings calls

    Credit ratings

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 31 Jan 2025 (unaudited). View the source filing. Figures are as filed and are not investment advice.